Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS-MMP9rx
- Development stage
- Discontinued
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
ISIS-MMP9rx (also known as ISIS 25302) is an antisense oligonucleotide developed by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals) designed to inhibit the production of matrix metalloproteinase-9 (MMP9). MMP9 is a type of enzyme that breaks down the extracellular matrix; while necessary for normal tissue remodeling, its overabundance in chronic wounds, such as diabetic foot ulcers, is associated with impaired healing. By specifically targeting and reducing MMP9 mRNA levels through an RNase H-dependent mechanism, ISIS-MMP9rx aims to restore the balance of tissue remodeling and promote wound closure. The drug was primarily investigated for the treatment of diabetic foot ulcers in Phase 2 clinical trials, though development has since been discontinued.
- Other names
- ISIS 25302ISIS25302ISIS-25302IONIS-MMP9-RxIONIS-MMP-9-RxIONIS-MMP 9-Rx
02
Targets
MMP9 (Matrix metalloproteinase-9)
Beyond the preview
Go deeper on ISIS-MMP9rx.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS-MMP9rx.